newsfilter
← Latest News
GlobeNewswire·

Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

  • Candel Therapeutics plans to submit a Biologics License Application (BLA) for aglatimagene in prostate cancer in mid-2027, pending FDA dialogue & assay refinement timelines.
  • Cash & cash equivalents of $203.1 million as of September 30, 2026, are expected to fund operations through Q2 2028.
  • Three poster presentations were accepted at the SITC 41st Annual Meeting, featuring data on aglatimagene in prostate cancer & NSCLC, and linoserpaturev in recurrent high-grade glioma (rHGG).
  • SITC data from the PrTK05 trial showed aglatimagene treatment triggers systemic activation of CD8+ T cells, including increased proliferation & expansion of memory T cells, with transient biodistribution & shedding.
  • New data from metastatic non-squamous NSCLC patients linked longitudinal immune changes & multi-omic features to survival beyond 24 months, complementing published phase 2a topline results.
  • Updated linoserpaturev phase 1b data for rHGG showed a median overall survival (mOS) of 12.0 months for single administrations (Arm A+B) & 14.3 months for multiple administrations (Arm C).
  • Biomarker analysis from the aglatimagene phase 3 prostate cancer trial revealed significantly increased intratumoral lymphocyte infiltration & tumor microenvironment remodeling compared to placebo.
  • Extended follow-up from the PrTK03 trial indicated a 41% reduction in recurrence or death risk for intermediate-risk prostate cancer patients treated with aglatimagene plus EBRT.
  • Candel initiated the first site of the global phase 3 AURORA trial for aglatimagene in metastatic non-squamous NSCLC, comparing the drug to standard-of-care docetaxel.
  • Martine Zimmermann was appointed to the Board in September 2026 to leverage her 30+ years of regulatory & quality expertise.
  • Maria Ostrovsky was appointed General Counsel in October 2026 to support BLA readiness & commercialization strategies.
  • Research & development expenses rose to $15.6 million in Q3 2026 from $8.5 million in Q3 2025 due to higher clinical trial & manufacturing costs.
  • General & administrative expenses increased to $7.4 million in Q3 2026 from $4.7 million in Q3 2025, driven by employee costs & commercial readiness spending.
  • The company reported a net loss of $21.9 million for Q3 2026, compared to $11.3 million in the same period last year.
Company
Candel Therapeutics, Inc
Keywords
Nasdaq:CADL, Candel Therapeutics, Inc, $CADL, BLA, CAN-2409, can-3110, prostate cancer, immunotherapy, immuno oncology